EW - Company ID 0001099800
The table below shows Edwards Lifesciences Corp's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B |
| Cost of revenue | $1.33B | $1.12B | $978.40M | $723.70M | $1.25B | $1.08B |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B |
| R&D | $1.08B | $1.05B | $962.90M | $843.60M | $903.10M | $760.70M |
Edwards Lifesciences Corp reported annual revenue of $6.07B for fiscal year 2025. That is up 11.5% from $5.44B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $2.96B (FY 2016) to $6.07B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.09B |
| $1.79B |
| $1.58B |
| $1.36B |
| $1.49B |
| $1.23B |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $897.60M |
| Income tax | $216.90M | $152.10M | $152.40M | $195.50M | $198.90M | $93.30M |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | - |
| EPS (diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 |